Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MSC033
MIFTS: 52

Muscle Disorders

Categories: Neuronal diseases, Muscle diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Muscle Disorders

About this section

MalaCards integrated aliases for Muscle Disorders:

Name: Muscle Disorders 38 43
Myopathy 73

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:
Sources

Summaries for Muscle Disorders

About this section
MedlinePlus : 43 Your muscles help you move and help your body work. Different types of muscles have different jobs. There are many problems that can affect muscles. Muscle disorders can cause weakness, pain or even paralysis. Causes of muscle disorders include Injury or overuse, such as sprains or strains, cramps or tendinitis A genetic disorder, such as muscular dystrophy Some cancers Inflammation, such as myositis Diseases of nerves that affect muscles Infections Certain medicines Sometimes the cause is not known.

MalaCards based summary : Muscle Disorders, also known as myopathy, is related to myopathy, congenital and congenital fiber-type disproportion, and has symptoms including back pain, leg cramps and muscle cramp. An important gene associated with Muscle Disorders is CLCN1 (Chloride Voltage-Gated Channel 1), and among its related pathways/superpathways are Focal Adhesion and Cardiac conduction. The drugs Benzocaine and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include Placenta, testes and brain, and related phenotype is muscle.

Sources

Related Diseases for Muscle Disorders

About this section

Diseases in the Muscle Disorders family:

Ano5-Related Muscle Diseases

Diseases related to Muscle Disorders via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Related Disease Score Top Affiliating Genes
1 myopathy, congenital 31.2 RYR1 SELENON TPM3
2 congenital fiber-type disproportion 30.9 RYR1 SELENON TPM3
3 central core disease of muscle 30.9 RYR1 RYR2 SELENON
4 myopathy, proximal, and ophthalmoplegia 30.3 COL6A1 COL6A2 RYR1
5 hypokalemic periodic paralysis, type 1 29.0 CLCN1 RYR1
6 muscular dystrophy 26.5 CAV3 COL6A1 COL6A2 COL6A3 MIR206 RYR1
7 myopathy 25.7 CAV3 CHKA CLCN1 COL6A1 COL6A2 COL6A3
8 multiminicore disease 10.5 RYR1 SELENON
9 myotonia congenita, autosomal dominant 10.5
10 miyoshi muscular dystrophy 1 10.5
11 myotonia congenita, autosomal recessive 10.5
12 myopathy, x-linked, with excessive autophagy 10.5
13 myopathy, vacuolar, with casq1 aggregates 10.5
14 familial periodic paralysis 10.5 CLCN1 RYR1
15 arrhythmogenic right ventricular dysplasia, familial, 2 10.5 RYR1 RYR2
16 brody myopathy 10.4 CLCN1 RYR1
17 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.4 PIK3C2A RYR1
18 myotonic disease 10.4 CLCN1 MIR206 RYR1
19 congenital structural myopathy 10.4 RYR1 SELENON TPM3
20 malignant hyperthermia 1 10.3
21 inclusion body myositis 10.3
22 myopathy, centronuclear, 1 10.3
23 myopathy, distal, 1 10.3
24 normokalemic periodic paralysis 10.3
25 stormorken syndrome 10.3
26 thyrotoxic periodic paralysis 1 10.3
27 muscular dystrophy, limb-girdle, type 2c 10.3
28 myopathy, centronuclear, 2 10.3
29 nemaline myopathy 2 10.3
30 fingerprint body myopathy 10.3
31 myopathy, centronuclear, x-linked 10.3
32 nemaline myopathy 6 10.3
33 nemaline myopathy 1 10.3
34 nemaline myopathy 4 10.3
35 neutral lipid storage disease with myopathy 10.3
36 myopathy, centronuclear, 3 10.3
37 myopathy, centronuclear, 4 10.3
38 nemaline myopathy 8 10.3
39 nemaline myopathy 9 10.3
40 myopathy, centronuclear, 5 10.3
41 muscular dystrophy, limb-girdle, type 2x 10.3
42 muscular dystrophy, limb-girdle, type 2w 10.3
43 myopathy, scapulohumeroperoneal 10.3
44 myopathy, distal, 5 10.3
45 myopathy, myofibrillar, 7 10.3
46 myopathy, centronuclear, 6, with fiber-type disproportion 10.3
47 multifocal motor neuropathy 10.3
48 left ventricular noncompaction 10.3
49 reducing body myopathy 10.3
50 foot drop 10.3

Graphical network of the top 20 diseases related to Muscle Disorders:



Diseases related to Muscle Disorders
Sources

Symptoms & Phenotypes for Muscle Disorders

About this section

UMLS symptoms related to Muscle Disorders:


back pain, leg cramps, muscle cramp, muscle rigidity, muscle spasticity, myoclonus, sciatica, torticollis, muscle weakness, spasmodic torticollis, musculoskeletal symptom, myalgia, joint symptom

MGI Mouse Phenotypes related to Muscle Disorders:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.23 COL6A1 COL6A3 RYR1 RYR2 SELENON TPM3
Sources

Drugs & Therapeutics for Muscle Disorders

About this section

Drugs for Muscle Disorders (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 766)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
7
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
8
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1 202409-33-4 123619
9
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
10
Ramipril Approved Phase 4 87333-19-5 5362129
11
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
12
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895
13
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
14
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
15
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
16
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
17
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
18
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
19
Sodium oxybate Approved Phase 4,Phase 3,Phase 2 502-85-2 5360545
20
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
21
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
22
Bezafibrate Approved, Investigational Phase 4,Phase 3,Phase 2 41859-67-0 39042
23
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
24
Polidocanol Approved Phase 4,Phase 2 9002-92-0
25
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 2216-51-5 16666
26
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 148553-50-8 5486971
27
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
28
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
29
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 103-90-2 1983
30
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
31
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
32
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 525-66-6 4946
33
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
34
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1134-47-0 2284
35
Azathioprine Approved Phase 4,Not Applicable 446-86-6 2265
36
Colchicine Approved Phase 4,Phase 3,Not Applicable 64-86-8 6167 2833
37
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 378-44-9 9782
38
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 9004-61-9 53477741
39
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1972-08-3 16078
40
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
41
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
42
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
43
Abatacept Approved Phase 4,Phase 3,Phase 2,Early Phase 1 332348-12-6 10237
44
Nitroglycerin Approved, Investigational Phase 4,Phase 2,Not Applicable 55-63-0 4510
45
Cortisone acetate Approved, Investigational Phase 4,Not Applicable 1950-04-4, 50-04-4 5745
46
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
47
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4205-90-7 2803
48
Budesonide Approved Phase 4 51333-22-3 63006 5281004
49
Gemfibrozil Approved Phase 4 25812-30-0 3463
50
Goserelin Approved Phase 4 65807-02-5 47725 5311128

Interventional clinical trials:

(show top 50) (show all 2792)
# Name Status NCT ID Phase Drugs
1 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4 Carnitine
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
4 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
5 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
6 A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon Unknown status NCT01341509 Phase 4
7 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
8 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
9 The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
10 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
11 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
12 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
13 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Unknown status NCT02757404 Phase 4
14 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
15 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
16 Corticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis Unknown status NCT02613455 Phase 4 Kenalog (triamcinolone);lidocaine 1% (lidocaine HCl 20mg)
17 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
18 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
19 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
20 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
21 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
22 Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis Unknown status NCT00173706 Phase 4 L-Carnitine Injection
23 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
24 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
25 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
26 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
27 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
28 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
29 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
30 Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00199745 Phase 4 atorvastatin
31 Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity Completed NCT00120055 Phase 4 Atorvastatin (Lipitor)
32 Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00414531 Phase 4 Atorvastatin
33 Using Clonidine to Improve Leg Weakness in People With Heart Failure Completed NCT00858845 Phase 4 Clonidine Patch
34 Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations Completed NCT01865500 Phase 4 Budesonide 4 mg;Budesonide 8 mg;Metil prednisolone
35 Effects of Vitamin D Supplementation in Obesity Completed NCT01037140 Phase 4 Cholecalciferol;placebo
36 Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects Completed NCT01385020 Phase 4 Gemfibrozil & red yeast rice (LipoCol)
37 Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial Completed NCT01372176 Phase 4
38 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4 Goserelin
39 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
40 Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy Completed NCT01553422 Phase 4
41 Shockwave Therapy of Chronic Achilles Tendinopathy Completed NCT00958620 Phase 4
42 "NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes" Completed NCT00792376 Phase 4 etoricoxib;diclofenac
43 The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial Completed NCT00761423 Phase 4
44 Achilles Tendinosis Study; Comparison of Radiofrequency to Surgical MicroDebridement Completed NCT00534781 Phase 4
45 The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy Completed NCT00377910 Phase 4 Aethoxysclerol
46 Colloids in Severe Trauma Completed NCT00890383 Phase 4 tetrastarch (Voluven)
47 Discomfort and Psychosocial Difficulties in Fibromyalgia Completed NCT02078791 Phase 4 Botox infiltration
48 Strengthening Exercises for Fibromyalgia Completed NCT02063750 Phase 4
49 Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
50 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine

Search NIH Clinical Center for Muscle Disorders

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Muscle Disorders cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Muscle Disorders:
PLX-PAD, placental-derived mesenchymal-like stromal cells for muscle disorders
Embryonic/Adult Cultured Cells Related to Muscle Disorders:
Placenta-derived adherent stromal cell (PLX) PMIDs: 18154467 19478280
Sources

Genetic Tests for Muscle Disorders

About this section
Sources

Anatomical Context for Muscle Disorders

About this section

MalaCards organs/tissues related to Muscle Disorders:

41
Testes, Brain, Heart, Spinal Cord, Bone, Skeletal Muscle, Kidney
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Muscle Disorders:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate
Sources

Publications for Muscle Disorders

About this section

Articles related to Muscle Disorders:

(show top 50) (show all 64)
# Title Authors Year
1
Interpreting Genetic Variants in Titin in Patients With Muscle Disorders. ( 29435569 )
2018
2
MR Imaging of Atraumatic Muscle Disorders. ( 29451848 )
2018
3
The potential of obscurin as a therapeutic target in muscle disorders. ( 28756711 )
2017
4
Fasciculations in nerve and muscle disorders - A prospective study of muscle ultrasound compared to electromyography. ( 29028499 )
2017
5
Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders. ( 28434044 )
2017
6
Muscle disorders: FGF19 reduces muscle wasting. ( 28729723 )
2017
7
Immunohistochemical analysis of canine and feline muscle disorders using formalin-fixed, paraffin-embedded tissues. ( 28599613 )
2017
8
Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels. ( 27179745 )
2016
9
Deficiency Of I+-actinin-3 Is Associated With Increased Incidence Of On Indirect Muscle Disorders/Injuries In Elite Football Players.: 2617 Board #140 June 3, 9: 30 AM - 11: 00 AM. ( 27361253 )
2016
10
Skeletal muscle disorders of glycogenolysis and glycolysis. ( 27231184 )
2016
11
Targeted massively parallel sequencing and histological assessment of skeletal muscles for the molecular diagnosis of inherited muscle disorders. ( 27600705 )
2016
12
The influence of psychological flexibility on life satisfaction and mood in muscle disorders. ( 27196863 )
2016
13
Muscle disorders: Preventing diaphragm dysfunction. ( 27681795 )
2016
14
Next-generation sequencing approaches for the diagnosis of skeletal muscle disorders. ( 27454578 )
2016
15
Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders. ( 27037223 )
2016
16
Genetic muscle disorders study. ( 27039558 )
2016
17
Diagnosis of late-onset Pompe disease and other muscle disorders by next-generation sequencing. ( 26809617 )
2016
18
203rd ENMC international workshop: Respiratory pathophysiology in congenital muscle disorders: Implications for pro-active care and clinical research 13-15 December, 2013, Naarden, The Netherlands. ( 25613806 )
2015
19
Taurine: the appeal of a safe amino acid for skeletal muscle disorders. ( 26208967 )
2015
20
Skeletal muscle perfusion and stem cell delivery in muscle disorders using intra-femoral artery canulation in mice. ( 26341268 )
2015
21
Common Creatine Kinase gene mutation results in falsely reassuring CK levels in muscle disorders. ( 26568611 )
2015
22
Editorial: Stem Cell-Based and Gene Therapy for Hereditary Muscle Disorders. ( 26206328 )
2015
23
Influence of the MCT1 rs1049434 on Indirect Muscle Disorders/Injuries in Elite Football Players. ( 26478856 )
2015
24
Regulating PPARI' Signaling as a Potential Therapeutic Strategy for Skeletal Muscle Disorders in Heart Failure. ( 25770240 )
2015
25
Congenital muscular dystrophies: New evidence-based guidelines for the diagnosis and management of this evolving group of muscle disorders. ( 25900129 )
2015
26
Muscle disorders: Combating cachexia in cancer. ( 26471368 )
2015
27
Issues & Opinions - The potential of psychological interventions to improve quality of life and mood in muscle disorders. ( 25297932 )
2014
28
K(V)7 potassium channels: a new therapeutic target in smooth muscle disorders. ( 24333708 )
2014
29
The Genetics of Skeletal Muscle Disorders in Horses. ( 25387114 )
2014
30
Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture. ( 24878976 )
2014
31
Loss-of-function mutations in MICU1 cause a brain and muscle disorder linked to primary alterations in mitochondrial calcium signaling. ( 24336167 )
2014
32
Human skeletal muscle xenograft as a new preclinical model for muscle disorders. ( 24452336 )
2014
33
Reining in nuclear factor-kappaB in skeletal muscle disorders. ( 23493016 )
2013
34
Nemaline myopathy in a newborn infant: a rare muscle disorder. ( 24166571 )
2013
35
Proteomic identification of biomarkers of skeletal muscle disorders. ( 23387498 )
2013
36
One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders. ( 22880633 )
2013
37
Quetiapine and cardiac muscle disorders. ( 23951594 )
2013
38
Creatine for treating muscle disorders. ( 23740606 )
2013
39
Muscle disorders: the latest investigations. ( 24004391 )
2013
40
Stem cell therapies for muscle disorders. ( 22918488 )
2012
41
Delineating the role of alterations in lipid metabolism to the pathogenesis of inherited skeletal and cardiac muscle disorders: Thematic Review Series: Genetics of Human Lipid Diseases. ( 22065858 )
2012
42
Masticatory muscle disorders diagnostic criteria: the American Academy of Orofacial Pain versus the research diagnostic criteria/temporomandibular disorders (RDC/TMD). ( 22882635 )
2012
43
Caveolinopathies: translational implications of caveolin-3 in skeletal and cardiac muscle disorders. ( 21496630 )
2011
44
Genetic variability of transcript abundance in pig peri-mortem skeletal muscle: eQTL localized genes involved in stress response, cell death, muscle disorders and metabolism. ( 22053791 )
2011
45
Delay in diagnosis of muscle disorders depends on the subspecialty of the initially consulted physician. ( 21542919 )
2011
46
Creatine for treating muscle disorders. ( 21328269 )
2011
47
Growing muscle has different sarcolemmal properties from adult muscle: a proposal with scientific and clinical implications: reasons to reassess skeletal muscle molecular dynamics, cellular responses and suitability of experimental models of muscle disorders. ( 21500235 )
2011
48
An internet-based system for home monitoring of respiratory muscle disorders. ( 21096291 )
2010
49
Deficiency of MIP/MTMR14 phosphatase induces a muscle disorder by disrupting Ca(2+) homeostasis. ( 19465920 )
2009
50
Eosinophilia-associated muscle disorders: an immunohistological study with tissue localisation of major basic protein in distinct clinicopathological forms. ( 19139036 )
2009
Sources

Variations for Muscle Disorders

About this section
Sources

Expression for Muscle Disorders

About this section
Search GEO for disease gene expression data for Muscle Disorders.
Sources

Pathways for Muscle Disorders

About this section

Pathways related to Muscle Disorders according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Focal Adhesion 37 1
Show member pathways
 12.47 CAV3 COL6A1 COL6A2 COL6A3
2
Cardiac conduction 66
Show member pathways